Non-arteritic Anterior Ischemic Optic Neuropathy

Citicoline 1000 mg will be repackaged and given to Group A for 60 days

Group A Citicoline 1000 mg oral tablet

Placebo will be repackaged and given to Group B for 60 days

Group B placebo oral tablet

Departemen Mata Fakultas Kedokteran Universitas Indonesia- RSCM Kirana

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study

amplitude measured from the valley of N35 to the peak of P50 with pattern electroretinography

amplitude measured from peak of P50 to valley of N95 with pattern electroretinography

anatomical cross-sectional examination of retinal ganglion cells using optical coherence tomography (OCT) CirrusTM HD-OCT 5000. The mode is panomap ganglion cell analysis: Macular Cube 512x128 and 200x200 cube Optic disc. Examination is repeated with minimal attention to signal strength is ≥ 5.

visual field test results using Humphrey HFA II-i 750, 24-2 threshold. Examination is repeated by taking into account the confidence index that meets the three criteria below:
Fixation losses ≤ 20%
False positive ≤ 15%
False negative ≤ 20-30%
The parameters assessed are:
The mean deviation (MD): the result of the average sensitivity of the retina of patients compared with the normal population. This figure is obtained from the total deviation.
Pattern standard deviation (PSD): the result of the average sensitivity of the retina of patients who have adapted and showed a localized area index. This figure is obtained from the pattern deviation.

Valen Chia

dr. Valenchia

Sample of 20 people for each treatment group (Group A: citicoline and group B : placebo). Both group were given drug (whether citicoline or placebo) for 60 days.

The allocation of the subject is done by using block randomization. Randomization will be performed by a third party before the study began. Number randomization results will be incorporated into the white envelope sealed and classified into group A (got citcoline) or group B (placebo) in accordance with the results of randomization. Neither the participant, investigator nor the outcome assessor know whether the patient is classified into group A or B.

Choline Deficiency

Vitamin B-12 Deficiency

Lipids Deficiency

Amino Acids Deficiency

A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.

Egg supplementation

Pastocalle Parish

Cracking the Egg Potential: Improving Young Child Nutrition in Ecuador

Qualitative assessments: focus groups; in-depth interviews

Washington University School of Medicine

Universidad San Francisco de Quito

Pan American Health Organization

University of California, Davis

1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)

2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)

Arthritis, Rheumatoid

Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.

FANG(30)

Placebo 30mg tabs, 3/day, 105 days continuously.

Placebo

Government of Chile - Science and Technology Development Fund (Study main sponsor)

HOSPITAL REGIONAL de OSORNO

Hospital Clínico Regional

Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients

Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients

All these data has been accepted for publication in Clinical Rheumatology

Juan C. Bertoglio, MD

Principal Investigator

Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Low Birth Weight Infant

University of Utah

Primary Children's Medical Center

Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression

Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression And The Incidence Of Chronic Lung Disease (Cld) In Very Low Birth Weight Infants

CLD will be defined as an oxygen requirement and abnormal x-ray findings. Investigations will compare outcomes of participants with genotypic variants of PAF-AH and those without known PAF-AH polymorphisms. Also, participant with biochemical evidence of PAF-AH dysregulation will be compared to those with normal PAF-AH protein and PAF concentrations.

The following clinical data will be collected and evaluated with respect to PAF-AH genotypic and phenotypic status: 1) length of time on mechanical ventilation; 2) length of time on oxygen therapy; 3) documented episodes of infection; 4) hemodynamically significant patent ductus arteriosus (PDA); 5) necrotizing enterocolitis (NEC); 6) retinopathy of prematurity (ROP); 7) intraventricular hemorrhage (IVH); 8) periventricular leukomalacia (PVL); 9) length of hospitalization; and 10) neurodevelopmental outcome.

phospholipid/ödem

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Cracking the Egg Potential: Improving Young Child Nutrition in Ecuador

Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients

Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen